Boundless Bio, Inc - BOLD Net earnings per one share for the last twelve months
The market for aggressive tumor treatments based on extrachromosomal DNA is in its infancy and possesses colossal demand potential. Boundless Bio, Inc. (BOLD) adheres to ESG standards by implementing energy-efficient cooling and reducing plastic use in its laboratories. Patent protection for the Inertia platform guarantees high margins for the therapy. The EPS YoY TTM growth rate reflects profit dynamics, with the value currently standing at 10.90.
Boundless Bio, Inc - analytical breakdowns and key metrics (BOLD)
- share price and expert price forecast:
- issuer market value details:
- company book value details:
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio Boundless Bio, Inc.|BOLD - Long-Term Debt to Capital|Short-Term Debt to Equity Boundless Bio Inc|BOLD - Company Aggregate Debts|Debts to Net Assets Boundless Bio Inc.|BOLD - Company Long-Term Debt|Short-Term Debt Boundless Bio|Intermediate Coverage Ratio boundlessbio.com
- business earnings and investment ratios data:
BOLD - Net Profit|Company Profit Forecast Boundless Bio, Inc.|BOLD - Price to Earnings Ratio|Price to Future Earnings Ratio Boundless Bio Inc.|BOLD - PEG Multiple|Enterprise Value to EBITDA Ratio Boundless Bio Inc.|BOLD - Operating profit before deduction of amortization|Net earnings per share for the last four quarters Boundless Bio|BOLD - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months boundlessbio.com|BOLD - Earnings per share growth in current year|Expected net earnings per share growth next year Boundless Bio, Inc.
Fundamental company valuation:BOLD (boundlessbio.com)
To stress-test assets, an investor compares actual profit with the annual change in rolling net income to isolate the effect of cheap loans from real demand. The stable operation of bio-centers and the development of IT clusters at Boundless Bio, Inc. (BOLD) confirm operational resilience, which can be assessed as the fundamental basis of business value through the eps YoY ttm growth efficiency metric.
Competitor analysis
TEM: Earnings per share for the last twelve months|QGEN: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Ionis Pharmaceuticals, Inc. (IONS)|Earnings per share for the last twelve months Repligen Corp.|Avidity Corp (RNA) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months CRISPR Therapeutics AG (CRSP)|Net earnings per share for the last four quarters genedx.com|Ultragenyx - Net earnings per share for the last 12 months|Earnings per share for the trailing year BEAM|Sarepta Therapeutics Inc - Net earnings per share (EPS TTM)|TWST: Earnings per share for the last twelve months|TXG: Net earnings per share (EPS TTM)|NTLA - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Stoke Therapeutics, Inc.|Net earnings per one share for the last twelve months BioLife Solutions Inc BLFS|Net earnings per share for the last 12 months WVE (Wave Life Sciences Corp)|MAZE (Maze Therapeutics Corp) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) SION (Sionna Therapeutics Inc)|Net earnings per share for the last four quarters primemedicine.com (PRME)|TSHA - Earnings per share for the last twelve months|QURE (uniQure NV) - Earnings per share for the last 12 months|MGTX: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months REGENXBIO Corp|Net earnings per share for the last 12 months SLDB|ocugen.com (OCGN) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) PACB|Earnings per share for the last twelve months BNTC (Benitec Biopharma Inc)|Earnings per share for the last twelve months Design Pharma DSGN|Rocket Corp (RCKT) - Net earnings per one share for the last twelve months|FDMT - Earnings per share for the last twelve months|LXEO: Earnings per share for the last twelve months|KRRO: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months EDIT|SLN (Silence Therapeutics Inc.) - Net earnings per share (EPS TTM)|Earnings per share for the last 12 months PRQR (ProQR Therapeutics NV)|Earnings per share for the last twelve months Codexis, Inc. (CDXS)|sangamo.com - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) NAUT (Nautilus Bio)|Net earnings per share (EPS TTM) Metagenomi Inc. MGX|Precision BioSciences - Net earnings per share (EPS TTM)|GBIO: Earnings per share for the last twelve months|exicuretx.com (XCUR) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Imunon (IMNN)|Net earnings per share for the last 12 months PHIO|Net earnings per share (EPS TTM) Mustang Bio Corp|Earnings per share for the last twelve months TransCode Therapeutics (RNAZ)|bionanogenomics.com - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) APDN (Applied DNA Sciences)|BLUE: Earnings per share for the last 12 months|IPA - Earnings per share for the last twelve months|OMGA: Earnings per share for the last twelve months|OMIC: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Regulus (RGLS)|Earnings per share for the last twelve months Syros Pharmaceuticals|telesisbio.com (TBIO) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months TRACON Pharmaceuticals, Inc. (TCON)|Net earnings per share for the last four quarters Unity Biotechnology Inc.
